News Highlights

News about and goings on at FUSION GENOMICS:

Fusion Genomics Receives $1 Million from CQDM To Study ONETest RTI Assay

We are pleased to share the news that Fusion Genomics has received a $1 million award to conduct a study evaluating our comprehensive, novel ONETest PathoGenome assay for the detection of pathogens associated with respiratory tract infections (RTIs). Due in great part to limitations associated with current diagnostic tests, RTIs are a leading cause of morbidity, mortality, and hospitalizations globally. Faster identification and diagnosis of pathogens responsible for these infections could help reduce their tremendous burden on patients and hospitals.

We are honored by CQDM’s decision to include the ONETest RTI assay among its prestigious portfolio of funded programs. The prospective clinical study, which we will conduct in partnership with Sunnybrook Research Institute, could help to transform the diagnosis and treatment of RTIs.

For more information, click here to read the news release we distributed this morning, and please don’t hesitate to contact us if you have any questions regarding this exciting new project.

Fusion Genomics Clinically Validating NGS Test for Infectious Disease; Eyes 2020 FDA Submission

GenomeWeb just published this article in their latest issue. It highlights our collaboration with Toronto’s Sunnybrook Research Institute to clinically validate our ONETest Rapid product that assays infectious diseases.

Processed with MOLDIV

It goes on to feature our new Series A funding round. Any monies raised will go to support additional clinical studies to validate our syndromic ONETest products for sepsis and nosocomial acquired infections.

Unfortunately, it’s behind GenomeWeb’s paywall but we’re excited to alert you to this news! Press like this is great for us! Please share the link!

Fusion Connects with China!

C2 iBridge interview with Fusion’s Mohammad Qadir

Fusion’s CSO, Dr Mohammad Qadir recently attended the Canada China Innovation & Investment Summit 2019 put together by C2CAN. Dr Qadir was recently interviewed in their September 2019 newsletter starting on page 6.

As the key organizer of the summit, C2CAN is a collaborative platform between SFU VentureLabsⓇ, China Canada Cleantech Innovation Centre (CCCIC), Tsinghua Holdings, and Hanhai Holdings. Its mission is to connect technology companies with the resources necessary to scale and succeed in China and Canada.

From the C2 iBridge website:

Through its new Canada China Innovation Bridge program (C2 iBridge), C2CAN aims to further its mission to promote cross-border collaboration in science and technology innovation between Canada and China.

​C2 Innovation & Investment Bridge (C2 iBridge) is a C2CAN program that focuses exclusively on events that support the C2CAN mission.